United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

24 Feb 2017
Change (% chg)

$0.13 (+2.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for CNAT.OQ


Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)


Beta: 1.43
Market Cap(Mil.): $129.03
Shares Outstanding(Mil.): 26.07
Dividend: --
Yield (%): --


  CNAT.OQ Industry Sector
P/E (TTM): -- 44.08 29.63
EPS (TTM): -1.26 -- --
ROI: -75.76 -3.35 12.96
ROE: -78.36 5.80 14.11

BRIEF-Conatus Pharmaceuticals says cfo Charles Cashion resigned

* On February 16, 2017, Charles J. Cashion tendered his resignation as chief financial officer Source text- http://bit.ly/2lfEBmE Further company coverage:

Feb 17 2017

BRIEF-Conatus Pharmaceuticals issued a convertible promissory note of $15 mln to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016

* Conatus Pharmaceuticals - On Feb 15, co issued a convertible promissory note of $15 million to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016 Source text: [http://bit.ly/2lpeTOz] Further company coverage:

Feb 16 2017

BRIEF-Conatus Pharmaceuticals promotes Daniel Ripley to senior vice president

* Conatus Pharmaceuticals promotes Daniel L. Ripley to senior vice president, business development, program and alliance management Source text for Eikon: Further company coverage:

Feb 02 2017

Conatus to receive $50 million in liver drug deal with Novartis

Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front.

Dec 19 2016

BRIEF-Conatus pharmaceuticals reports Q3 loss per share $0.31

* Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S

Nov 08 2016

BRIEF-Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID to Monitor Patients with Cirrhosis Associated with NASH

* Exalenz Bioscience announces collaboration with Conatus Pharmaceuticals to use BreathID to monitor patients with cirrhosis associated with NASH

Aug 29 2016

More From Around the Web


  Price Chg
BASF SE (BASFn.DE) €87.36 -2.59
Johnson & Johnson (JNJ.N) $122.73 +1.03
Novartis AG (NOVN.S) CHF77.60 0.00
Merck & Co., Inc. (MRK.N) $66.16 +0.31
Roche Holding Ltd. (ROG.S) CHF245.20 +0.10
Roche Holding Ltd. (RO.S) CHF248.50 +0.30

Earnings vs. Estimates